Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

MLA

Mundt, Filip, et al. “Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.” Cancer Research, vol. 78, no. 10, May 2018, pp. 2732–46. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-17-1990.

APA

Mundt, F., Rajput, S., Li, S., Ruggles, K. V., Mooradian, A. D., Mertins, P., Gillette, M. A., Krug, K., Guo, Z., Hoog, J., Erdmann-Gilmore, P., Primeau, T., Huang, S., Edwards, D. P., Wang, X., Wang, X., Kawaler, E., Mani, D. R., Clauser, K. R., … Ma, C. X. (2018). Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Research, 78(10), 2732–2746. https://doi.org/10.1158/0008-5472.CAN-17-1990

Chicago

Mundt, Filip, Sandeep Rajput, Shunqiang Li, Kelly V Ruggles, Arshag D Mooradian, Philipp Mertins, Michael A Gillette, et al. 2018. “Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.” Cancer Research 78 (10): 2732–46. doi:10.1158/0008-5472.CAN-17-1990.